Lloyd Kelland

Summary

Affiliation: Cranmer Terrace
Country: UK

Publications

  1. ncbi request reprint Farnesyl transferase inhibitors in the treatment of breast cancer
    Lloyd R Kelland
    Department of Bioscience, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 OQS, UK
    Expert Opin Investig Drugs 12:413-21. 2003
  2. ncbi request reprint EuroTIDES 2005--Sixth Annual IBC Conference
    Lloyd Kelland
    Antisoma plc, West Africa House, Hanger Lane, Ealing, London, W5 3QR, UK
    IDrugs 9:101-4. 2006
  3. ncbi request reprint Emerging drugs for ovarian cancer
    Lloyd R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 0QS, UK
    Expert Opin Emerg Drugs 10:413-24. 2005
  4. ncbi request reprint Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development
    L R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London SW17 OQS, UK
    Eur J Cancer 40:827-36. 2004
  5. ncbi request reprint Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects
    Lloyd R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London SW17 OQS, UK
    Eur J Cancer 41:971-9. 2005
  6. ncbi request reprint Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin
    Lloyd Kelland
    University College London, Wolfson Institute for Biomedical Research, Cancer Research Technology Development Laboratories, London, UK
    Expert Opin Investig Drugs 16:1009-21. 2007
  7. ncbi request reprint The resurgence of platinum-based cancer chemotherapy
    Lloyd Kelland
    Cancer Research Technology Development Laboratories, Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK
    Nat Rev Cancer 7:573-84. 2007
  8. ncbi request reprint Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization
    Lloyd Kelland
    University College London, Cancer Research Technology Development Laboratories, Gower Street, WCV1E 6BT, London, UK
    Curr Opin Mol Ther 9:86-91. 2007
  9. ncbi request reprint G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo
    Mekala Gunaratnam
    CRUK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Biochem Pharmacol 78:115-22. 2009
  10. ncbi request reprint Discovery and development of anticancer aptamers
    Christopher R Ireson
    Antisoma Research Laboratories, London, UK
    Mol Cancer Ther 5:2957-62. 2006

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Farnesyl transferase inhibitors in the treatment of breast cancer
    Lloyd R Kelland
    Department of Bioscience, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 OQS, UK
    Expert Opin Investig Drugs 12:413-21. 2003
    ..It is likely that the future clinical direction of FTIs will be as combination therapy, especially with the taxanes, where synergy has been seen in a variety of preclinical studies...
  2. ncbi request reprint EuroTIDES 2005--Sixth Annual IBC Conference
    Lloyd Kelland
    Antisoma plc, West Africa House, Hanger Lane, Ealing, London, W5 3QR, UK
    IDrugs 9:101-4. 2006
  3. ncbi request reprint Emerging drugs for ovarian cancer
    Lloyd R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 0QS, UK
    Expert Opin Emerg Drugs 10:413-24. 2005
    ..g., 5,6-dimethyl xanthenone 4-acetic acid). At the pre-clinical level, agents being developed to target the phosphatidylinositol 3 kinase/AKT/mTOR pathway, and K-Ras inhibitors, may offer efficacy in the future...
  4. ncbi request reprint Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development
    L R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London SW17 OQS, UK
    Eur J Cancer 40:827-36. 2004
    ..g. inhibitors of the metastatic process and anti-angiogenic strategies as the vasculature is of murine origin)...
  5. ncbi request reprint Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects
    Lloyd R Kelland
    Antisoma Research Laboratories, St Georges Hospital Medical School, Cranmer Terrace, London SW17 OQS, UK
    Eur J Cancer 41:971-9. 2005
    ..g., GRN163L) and from the distinct class of those targeting telomeres (e.g., AS1410 based on BRACO19) will enter Phase I clinical trial where clinical benefit from this class of novel drugs will be determined...
  6. ncbi request reprint Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin
    Lloyd Kelland
    University College London, Wolfson Institute for Biomedical Research, Cancer Research Technology Development Laboratories, London, UK
    Expert Opin Investig Drugs 16:1009-21. 2007
    ..g., the recent approval of the vascular endothelial growth factor monoclonal antibody bevacizumab with carboplatin and paclitaxel in patients with NSCLC)...
  7. ncbi request reprint The resurgence of platinum-based cancer chemotherapy
    Lloyd Kelland
    Cancer Research Technology Development Laboratories, Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK
    Nat Rev Cancer 7:573-84. 2007
    ....
  8. ncbi request reprint Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization
    Lloyd Kelland
    University College London, Cancer Research Technology Development Laboratories, Gower Street, WCV1E 6BT, London, UK
    Curr Opin Mol Ther 9:86-91. 2007
    ..By May 2005, ADH-1 was in phase Ib/II clinical trials in Europe and the US, and phase II clinical trials in Canada...
  9. ncbi request reprint G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo
    Mekala Gunaratnam
    CRUK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London, WC1N 1AX, UK
    Biochem Pharmacol 78:115-22. 2009
    ....
  10. ncbi request reprint Discovery and development of anticancer aptamers
    Christopher R Ireson
    Antisoma Research Laboratories, London, UK
    Mol Cancer Ther 5:2957-62. 2006
    ..In preclinical studies, additional aptamers have been described against several cancer targets, such as tenascin-C, the transcription factor signal transducer and activator of transcription 3, and antiapoptotic and Ku proteins...
  11. ncbi request reprint SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity
    John A Hartley
    Cancer Research UK Drug DNA Interactions Research Group, Department of Oncology, Royal Free and University College Medical School, London, United Kingdom
    Cancer Res 64:6693-9. 2004
    ..v. administration. The level of cross-linking persists over a 24-hour period in this tumor in contrast to cross-links produced by conventional cross-linking agents observed over the same time period...
  12. ncbi request reprint Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy
    Lesley D McPhail
    Department of Basic Medical Sciences, St George s Hospital Medical School and Antisoma Research, Ltd, London, United Kingdom
    Clin Cancer Res 11:3705-13. 2005
    ....
  13. ncbi request reprint Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Invest New Drugs 25:271-6. 2007
    ..Its action is incompletely understood and we wished to develop an in vitro system to study its effects...
  14. ncbi request reprint Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents
    Cristina Martins
    CRUK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, United Kingdom
    Bioorg Med Chem Lett 17:2293-8. 2007
    ..Replacement of the previously reported anilino substituents by benzylamino groups results in enhanced quadruplex interaction, and for one compound, superior telomerase inhibitory activity...
  15. ncbi request reprint Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor
    Christopher M Incles
    The School of Pharmacy, 29 39 Brunswick Square, London WC1N 1AX, UK
    Mol Pharmacol 64:1101-8. 2003
    ....
  16. ncbi request reprint Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)]
    Jose M Perez
    Departamento de Quimica Inorganica, Facultad de Ciencias, Universidad Autonoma de Madrid, Cantoblanco, Madrid, Spain
    Mol Pharmacol 63:933-44. 2003
    ..Therefore, the lack of in vivo antitumor activity shown by compound 1 might be related to its extracellular inactivation before reaching the tumor site because of its high rate of binding to plasma proteins...
  17. ncbi request reprint Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo
    Paul M Rogers
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Int J Cancer 97:858-63. 2002
    ..Such effects may be missed in vitro when using short-term growth inhibition or clonogenic assays...
  18. ncbi request reprint A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity
    Sharon M Gowan
    Cancer Research Campaign CRC Center for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom
    Mol Pharmacol 61:1154-62. 2002
    ....
  19. ncbi request reprint Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug
    Jane M Berry
    CRUK Gene Targeted Drug Design Research Group, Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, University Park, NG7 2RD, Nottingham, UK
    Bioorg Med Chem Lett 12:1413-6. 2002
    ..This prototype could lead to a new generation of clinically useful N10-protected PBD prodrugs...
  20. ncbi request reprint Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line
    Victoria Smith
    CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton SM2 5NG, UK
    Clin Cancer Res 8:2002-9. 2002
    ..The results suggest that the development of clinical resistance may occur with farnesyl protein transferase inhibitors...
  21. pmc Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis
    Lesley D McPhail
    Division of Basic Medical Sciences, St George s, University of London, London, UK
    Neoplasia 8:199-206. 2006
    ..The absence of any reduction in K(trans) or IAUGC following treatment with 200 mg/kg, despite a significant increase in 5-HIAA, raises concerns about the utility of established DCE-MRI biomarkers to assess tumor response to DMXAA...
  22. ncbi request reprint Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol
    Kathryn Nicoll
    WestCHEM, Department of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK
    Oncol Res 16:97-106. 2006
    ..Assays of some of the compounds as substrates for tyrosinase showed that the catechol 18 was the best substrate and that the piperidine derivative 7 was the best substrate of the phenolic compounds synthesized...
  23. pmc Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity
    Alexander Hegmans
    Department of Chemistry, Virginia Commonwealth University, Richmond, VA 23284 2006, USA
    J Med Chem 51:2254-60. 2008
    ..The properties of the compounds present them also as possible "second-generation" analogues of the clinically relevant trinuclear complex [{ trans-PtCl(NH 3) 2} 2-mu- trans-Pt(NH 3) 2(NH 2(CH 2) 6NH 2) 2](NO 3) 4, ( 8, BBR3464)...
  24. ncbi request reprint Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile
    Erin S F Ma
    Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284 2006, USA
    J Med Chem 48:5651-4. 2005
    ..The new compounds are the first cytotoxic transplatinum compounds containing an N(2)O(2) donor set, similar to carboplatin and oxaliplatin...
  25. ncbi request reprint Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol
    Jillian Ferguson
    Department of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK
    Oncol Res 15:87-94. 2005
    ..The cyclohexanecarboxamides were better substrates for mushroom tyrosinase (EC 1.14.18.1) than the acetamides...
  26. ncbi request reprint ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin
    Vicki Smith
    CRC Center for Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
    Anticancer Res 22:1993-9. 2002
    ..These data suggest that erbB2 status in ovarian cancr may contribute to chemosensitivity, in some cases leading to increased sensitivity (as with geldanamycin) but in other cases leading to resistance (as with cisplatin)...
  27. ncbi request reprint Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore
    Michael D Urbaniak
    Center for Biomolecular Design and Drug Development, School of Chemistry, University of Sussex, Falmer, Brighton, BN1 9QJ, UK
    Bioorg Med Chem Lett 13:2025-7. 2003
    ..Those compounds containing a cyclopentenone moiety were active, with the carbonyl group being essential for biological activity...
  28. ncbi request reprint Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol
    Vikki C Pearson
    Department of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK
    Oncol Res 13:503-12. 2003
    ..The moderate activity of 13-16 against SK-Mel-24 (non-tyrosinase containing) and an ovarian cell line suggests that interference with the melanin pathway may not be the only mode of action of these new compounds...
  29. ncbi request reprint Trisubstituted acridine derivatives as potent and selective telomerase inhibitors
    R John Harrison
    Cancer Research UK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London, WC1N 1AX, U K
    J Med Chem 46:4463-76. 2003
    ..These data support a model for the action of these compounds that involves the stabilization of intermediate quadruplex structures that inhibit the elongation of telomeric DNA by telomerase in tumor cells...
  30. ncbi request reprint Bioreductive prodrugs for cancer therapy
    Beatrice Seddon
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK
    Methods Mol Med 90:515-42. 2004
  31. ncbi request reprint Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells
    Klaus Pors
    Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, 29 39 Brunswick Square, University of London, London WC1N 1AX, UK
    J Med Chem 47:1856-9. 2004
    ..All the 1,4-disubstituted chloroethylaminoanthraquinones were potently cytotoxic (nM IC(50)s) against cisplatin-resistant ovarian cancer cell lines...
  32. ncbi request reprint A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells
    Christopher M Incles
    Cancer Research UK Biomolecular Structure Group, School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Mol Cancer Ther 3:1201-6. 2004
    ..We also show that treatment with BRACO-19 causes extensive end-to-end chromosomal fusions, consistent with telomere uncapping...
  33. ncbi request reprint Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding
    R John Harrison
    Cancer Research UK Biomolecular Structure Group, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    Bioorg Med Chem Lett 14:5845-9. 2004
    ..It is concluded that telomerase inhibitory activity is a necessary though by itself insufficient property in order for cellular growth arrest to occur at sub-toxic concentrations, and that tight quadruplex binding is also required...
  34. ncbi request reprint Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Int J Cancer 116:322-6. 2005
    ..DMXAA might be useful clinically to potentiate the vascular permeability of other anticancer modalities such as cytotoxic drugs, antibodies, drug conjugates and gene therapy...
  35. ncbi request reprint In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202
    Florence I Raynaud
    Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Haddow Laboratories, Belmont, Sutton, United Kingdom
    Clin Cancer Res 11:4875-87. 2005
    ..To investigate pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine, and CYC202 (R-roscovitine; seliciclib) in the HCT116 human colon carcinoma model...
  36. ncbi request reprint Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts
    Robert A Heald
    Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, UK
    J Med Chem 45:590-7. 2002
    ..Compound 12d is soluble in water, stable in the pH range of 5-9, efficiently transported into tumor cells, and is currently the lead structure for further elaboration in this new class of telomerase inhibitor...